Saxagliptin + Metformin

Details

Files

Generic Name:

Saxagliptin + metformin

Project Status:

Complete

Therapeutic Area:

Diabetes Mellitus, type 2

Manufacturer:

AstraZeneca Canada Inc.

Call for patient/clinician input open:

August 26, 2013

Brand Name:

Komboglyze

Project Line:

Reimbursement Review

Project Number:

SR0348-000

Call for patient/clinician input closed:

September 17, 2013

NOC Status at Filing:

Post NOC

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Diabetes Mellitus, Type 2

Recommendation Type:

List with criteria/condition

Final Recommendation:

June 20, 2014

Files

Recommendation and Reasons: Updated View PDF

Submission Status Report View PDF

Recommendation and Reasons: Original View PDF

Fixed-Dose Combination Review Report View PDF

Last Updated : March 22, 2024